title: Treatment of penicillin-resistant Neisseria gonorrhoeae with oral norfloxacin.
abstract: Norfloxacin, an orally administered quinoline carboxylic acid that is structurally related to nalidixic acid, has been shown to be highly active in vitro against penicillinase-producing Neisseria gonorrhoeae. Ninety-two men with culture-proved gonococcal urethritis, 46 per cent with penicillinase-producing N. gonorrhoeae, and 27 per cent with non-penicillinase-producing N. gonorrhoeae that was resistant to penicillin were given either 1200 mg of norfloxacin divided into two equal oral doses four hours apart (59 patients) or 2 g of spectinomycin intramuscularly (33 patients). All patients in both treatment groups were cured. No adverse reactions were reported in either group. We conclude that a two-dose, single-day regimen of orally administered norfloxacin is effective therapy for uncomplicated urethritis caused by penicillin-resistant strains of N. gonorrhoeae.
mesh_terms: D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004361:Drug Tolerance; D006069:Gonorrhea / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D008297:Male; D009268:Nalidixic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009344:Neisseria gonorrhoeae / Q000187:drug effects; D009643:Norfloxacin; D010403:Penicillin Resistance; D010406:Penicillins / Q000494:pharmacology; D000198:Spectinomycin / Q000627:therapeutic use; D014526:Urethritis / Q000188:drug therapy
chemical_list: D000900:Anti-Bacterial Agents; D010406:Penicillins; D009268:Nalidixic Acid; D000198:Spectinomycin; D009643:Norfloxacin